by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
Fifty years after political and cultural winds slammed shut the doors on psychedelic research, UC Berkeley is making up for lost time by launching the campus’s first center for psychedelic science and public education. With $1.25 million in seed funding from an...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
On May 7, 2019, the city of Denver made headlines for becoming the first U.S. city to effectively decriminalize psilocybin mushrooms through its passing of Initiated Ordinance 301 (I-301). In the months that followed, Oakland and Santa Cruz followed suit,...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
Psilocybin has been fast-tracked by the FDA to become a prescription medication in psychedelic-assisted therapy for depression, but now we’re seeing investors line up to support a new indication for the synthetic compound that’s been made famous—in its organic form—by...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
A new study is presenting the first published data from preliminary human trials investigating the effect of psilocybin-assisted psychotherapy to treat major depressive disorder (MDD). The incredibly positive results have been described as just a “taste of things to...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
MycoMeditations is a psychedelic-retreat company in Treasure Beach, Jamaica, that facilitates 10-day trips where attendees take psychedelic, or “magic,” mushrooms. Recent research has suggested that magic mushrooms, which contain the psychedelic compound...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
There is a magical moment in the pharmaceutical industry when a government approves a new treatment. For companies researching psilocybin, the psychoactive component in psychedelic mushrooms, that moment is now. Late last year, the United States Food and Drug...
